Research to watch, not an owner-directed longevity treatment.
The atlas separates a biological hypothesis, a canine or feline measurement, a controlled clinical result and a commercial longevity claim. They are not interchangeable.
What was actually measured?
Lifespan Primary Purpose; Health Measures Secondary Purpose
multicentre randomised controlled clinical trialTRIAD is a double-blind, placebo-controlled trial of rapamycin in companion dogs.
generally healthy, older companion dogs meeting trial criteria · efficacy result not yet established in the cited official material
LimitationTrial participation criteria do not define routine clinical use.
Safety And Use Boundary
official trial guidanceThe official participant guidance says the effect on canine health and ageing is currently unknown and does not recommend owner-directed use.
companion dogs outside the trial · use outside monitored research is not recommended by the study team
LimitationGuidance is not a completed efficacy analysis.
No human-to-pet conversion.
No dose is provided. The Dog Aging Project states that it cannot ethically recommend use for age-related decline outside the monitored trial.
“Pet supplement” is not a universal legal category.
FDA does not recognise a separate dietary-supplement category for animal products; depending on intended use, products are regulated as animal food or animal drugs. Disease-treatment or prevention claims can indicate new-animal-drug intent.
Open FDA source →Trace every material statement.
Page data version: 2026-08-18. Medical review is not claimed without a named sign-off.